Driving toward a sustainable future

We’re committed to delivering more aggressive emission reduction goals.

See why

Our History

Explore where we’ve been and how we continue to go beyond medicine to make a remarkable impact.

Learn more

Latest news

If you are a member of the news media and have questions or need additional information, please contact our communications team.

Dec 06, 2021

Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease

Dec 03, 2021

AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S.

Nov 30, 2021

AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)

Nov 30, 2021

The Alliance for Endometriosis Survey Reveals Actions Needed to Improve the Endometriosis Patient Experience
Read More

You must be logged in to view this item.

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?